Niagen Bioscience Inc expected to post earnings of 1 cent a share - Earnings Preview
Niagen Bioscience Inc
NAGE is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2025The Los Angeles California-based company is expected to report a 24.6% increase in revenue to $28.324 million from $22.74 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Niagen Bioscience Inc is for earnings of 1 cent per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Niagen Bioscience Inc is $16.00, about 39.8% above its last closing price of $9.64
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | 0.02 | 0.02 | 0.06 | Beat | 259.9 |
Dec. 31 2025 | 0.02 | 0.02 | 0.09 | Beat | 350 |
Sep. 30 2024 | 0.01 | 0.00 | 0.02 | Beat | 500.6 |
Jun. 30 2024 | -0.02 | -0.02 | 0.00 | Beat | 100 |
Mar. 31 2024 | -0.02 | -0.02 | -0.01 | Beat | 40 |
Dec. 31 2023 | -0.03 | -0.03 | 0.00 | Beat | 100 |
Sep. 30 2023 | -0.03 | -0.03 | -0.01 | Beat | 69.2 |
Jun. 30 2023 | -0.04 | -0.04 | -0.03 | Beat | 20 |
This summary was machine generated August 4 at 23:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
